WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice

The global prevalence of nonalcoholic steatohepatitis (NASH) increases incredibly. NASH ends up to advanced liver disease, which is highly threatening to human health. Currently, treatment of NASH is very limited. Acetyl-CoA carboxylases (ACC1/ACC2) are proved as effective drug targets for NASH. We...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Acta Pharmacol Sin
Autores principales: Gao, Ying-sheng, Qian, Min-yi, Wei, Qiang-qiang, Duan, Xu-bin, Wang, Shi-lei, Hu, Hai-yang, Liu, Jun, Pan, Chu-yue, Zhang, Shuo-quan, Qi, Lian-wen, Zhou, Jin-pei, Zhang, Hui-bin, Wang, Li-rui
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Singapore 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7468331/
https://ncbi.nlm.nih.gov/pubmed/31645659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-019-0310-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares